Germany Based Evotec Sets Terms For $576M US IPO

  • German biotech Evotec SE EVTCY plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $9.2 billion. 
  • See the SEC offer prospectus here.
  • The Company plans to list on the NASDAQ under the symbol EVO.
  • Evotec plans to use $100 million from the IPO proceeds to expand a biologics manufacturing facility in Redmond, Washington, $175 million for building additional capacity in France, $115 million for solo R&D, $80 million for equity investments, and the list goes on.
  • The Company works as a drug discovery, and development partner to the pharmaceutical and biotechnology industry focused on discovering drug candidates in a wide range of difficult-to-treat diseases. 
  • It generates income by charging fees for its services, collecting milestones & royalties, and equity ownership in biotechs. 
  • Evotec states that its pipeline has over 130 assets.
  • Most recently: Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate.
  • Price Action: EVTCY shares are down 2.91% at $24 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapIPOsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!